Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Michael Richard Verneris

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS
Email

    Collapse Biography 
    Collapse education and training
    Syracuse Univeristy, Syracuse, NYBS1987Biology/Psychology
    Dartmouth-Brown Program In Medicine, Hanover, NH/Providence, RIMD1992Medicine
    Children's National Medical Center, Washington, DC1995Pediatric Residency
    Stanford University, Palo Alto, CA2002Pediatric Hematology/Oncology and Bone Marrow Transplantation

    Collapse Overview 
    Collapse overview
    Our laboratory is focused on using the immune system to target and treat cancer. Active projects in the laboratory include:

    1) Chimeric antigen receptor expressing T cell (CART) homing to solid tumors

    2) Chimeric antigen receptor expressing iPS and ES cells that are differentiated into natural killer (NK) and T cells

    3) Animal models of bone marrow transplantation

    Collapse Research 
    Collapse research activities and funding
    UG1HL174426     (STEFANSKI, HEATHER E)Aug 15, 2024 - Jun 30, 2031
    NIH
    BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening Diseases
    Role: Co-Principal Investigator
    R01HL155691     (VERNERIS, MICHAEL R.)Sep 18, 2020 - Mar 31, 2025
    NIH
    Characterizing Innate Immune Dysregulation in Tonsils of Individuals with Down Syndrome
    Role: Principal Investigator
    R01CA196754     (SPECTOR, LOGAN G.)Jul 1, 2015 - Jun 30, 2019
    NIH
    Genetic epidemiology of hematopoietic cell transplant outcomes
    Role: Co-Principal Investigator
    R03CA195618     (VERNERIS, MICHAEL R.)Apr 1, 2015 - Mar 31, 2018
    NIH
    Biomarkers In Pediatric Versus Adult Myelodysplastic Syndromes
    Role: Principal Investigator
    R01AI100879     (VERNERIS, MICHAEL R.)May 15, 2013 - Apr 30, 2019
    NIH
    Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune Recovery
    Role: Principal Investigator
    K08HL004505     (VERNERIS, MICHAEL R)Apr 6, 2001 - Mar 31, 2006
    NIH
    ACTIVITY OF EXPANDED GAMMA/DELTA T CELLS
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Baumeister S, Verneris MR, Myers GD, Karras NA, Cooper S, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Fabrizio V, Chinnabhandar V, Kunicki M, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023 Nov; 65:102268. PMID: 37954907.
      View in: PubMed
    2. McNerney KO, Moskop A, Winestone LE, Baggott C, Talano JA, Schiff D, Rossoff J, Modi A, Verneris MR, Laetsch TW, Schultz L. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 Jan; 30(1):75.e1-75.e11. PMID: 37816472.
      View in: PubMed
    3. McNerney KO, Si Lim SJ, Ishikawa K, Dreyzin A, Vatsayan A, Chen JJ, Baggott C, Prabhu S, Pacenta HL, Philips C, Rossoff J, Stefanski HE, Talano JA, Moskop A, Verneris M, Myers D, Karras NA, Brown P, Bonifant CL, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Baumeister SHC, Fabrizio VA, Chinnabhandar V, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Adv. 2023 06 27; 7(12):2758-2771. PMID: 36857419.
      View in: PubMed
    4. Cruz Cruz J, Allison KC, Page LS, Jenkins AJ, Wang X, Earp HS, Frye SV, Graham DK, Verneris MR, Lee-Sherick AB. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Front Immunol. 2023; 14:1146721. PMID: 36960055.
      View in: PubMed
    5. Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023 02 28; 7(4):575-585. PMID: 35482927.
      View in: PubMed
    6. Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski MC, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023 02 28; 7(4):541-548. PMID: 35938863.
      View in: PubMed
    7. Murphy LA, Miller K, Winters AC, Franklin ARK, Verneris MR, Keating AK. Time to transplantation and pediatric acute myeloid leukemia outcomes. Bone Marrow Transplant. 2023 03; 58(3):343-345. PMID: 36496523.
      View in: PubMed
    8. McLaughlin L, DeZoeten E, Verneris MR. Can allogeneic haematopoietic cell transplantation be curative in classical Crohn's disease? Br J Haematol. 2023 03; 200(5):541-542. PMID: 36352551.
      View in: PubMed
    9. Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023 01 10; 41(2):354-363. PMID: 36108252.
      View in: PubMed
    10. Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022 09 13; 6(17):5222-5226. PMID: 35834728.
      View in: PubMed
    11. Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4251-4255. PMID: 35580324.
      View in: PubMed
    12. Shim SH, Tufa D, Woods R, George TD, Shank T, Yingst A, Lake J, Cobb L, Jones D, Jones K, Verneris MR. SAHA Enhances Differentiation of CD34+CD45+ Hematopoietic Stem and Progenitor Cells from Pluripotent Stem Cells Concomitant with an Increase in Hemogenic Endothelium. Stem Cells Transl Med. 2022 05 27; 11(5):513-526. PMID: 35349707.
      View in: PubMed
    13. Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):1961-1968. PMID: 34788386.
      View in: PubMed
    14. Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 01 25; 6(2):600-610. PMID: 34794180.
      View in: PubMed
    15. Verneris MR, Ma Q, Zhang J, Keating A, Tiwari R, Li J, Yang H, Agarwal A, Pacaud L. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2021 12 14; 5(23):5387-5395. PMID: 34597381.
      View in: PubMed
    16. Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955. PMID: 34882493.
      View in: PubMed
    17. Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 11 25; 138(21):2138-2142. PMID: 34499715.
      View in: PubMed
    18. Wagner JE, Ballen KK, Zhang MJ, Allbee-Johnson M, Karanes C, Milano F, Verneris MR, Eapen M, Brunstein CG. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv. 2021 10 26; 5(20):4064-4072. PMID: 34461630.
      View in: PubMed
    19. Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 11; 27(11):926.e1-926.e10. PMID: 34407489.
      View in: PubMed
    20. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08; 27(8):642-649. PMID: 34304802.
      View in: PubMed
    21. Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH, Maude SL. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer. 2021 08; 9(8). PMID: 34353848.
      View in: PubMed
    22. Spector LG, Spellman SR, Thyagarajan B, Beckman KB, Hoffmann C, Garbe J, Hahn T, Sucheston-Campbell L, Richardson M, De For TE, Tolar J, Verneris MR. Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR. Transplant Cell Ther. 2021 10; 27(10):836.e1-836.e7. PMID: 34174468.
      View in: PubMed
    23. Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021 04; 9(4). PMID: 33846220.
      View in: PubMed
    24. Mar?n-Jim?nez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021; 12:607282. PMID: 33854497.
      View in: PubMed
    25. Cobb LM, Verneris MR. Therapeutic manipulation of innate lymphoid cells. JCI Insight. 2021 03 22; 6(6). PMID: 33749662.
      View in: PubMed
    26. Christakopoulos GE, DeFor TE, Hage S, Wagner JE, Linden MA, Brunstein C, Bejanyan N, Verneris MR, Smith AR. Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation. Transplant Cell Ther. 2021 06; 27(6):497.e1-497.e6. PMID: 33785364.
      View in: PubMed
    27. Qayed M, Ahn KW, Kitko CL, Johnson MH, Shah NN, Dvorak C, Mellgren K, Friend BD, Verneris MR, Leung W, Toporski J, Levine J, Chewning J, Wayne A, Kapoor U, Triplett B, Schultz KR, Yanik GA, Eapen M. A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood. 2021 02 18; 137(7):983-993. PMID: 33206937.
      View in: PubMed
    28. Haynes AS, Curtis DJ, Campbell K, Giller RH, Quinones RR, Verneris MR, Abzug MJ. An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT. Transplant Cell Ther. 2021 04; 27(4):317-326. PMID: 33836875.
      View in: PubMed
    29. Koo J, Hayashi M, Verneris MR, Lee-Sherick AB. Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment. Front Oncol. 2020; 10:581107. PMID: 33381449.
      View in: PubMed
    30. Tufa DM, Yingst AM, Trahan GD, Shank T, Jones D, Shim S, Lake J, Winkler K, Cobb L, Woods R, Jones K, Verneris MR. Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling. Sci Immunol. 2020 11 20; 5(53). PMID: 33219153.
      View in: PubMed
    31. Baik J, Felices M, Yingst A, Theuer CP, Verneris MR, Miller JS, Perlingeiro R. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct; 6(10):e05242. PMID: 33088975.
      View in: PubMed
    32. Dhakal B, Wang T, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon YT, Carlson KS, Nazha A, Saber W. Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021 01; 62(1):229-233. PMID: 32924688.
      View in: PubMed
    33. Sopfe J, Campbell K, Keating AK, Pyle L, Liu AK, Verneris MR, Giller RH, Forlenza GP. Glycemic variability is associated with poor outcomes in pediatric hematopoietic stem cell transplant patients. Pediatr Blood Cancer. 2020 11; 67(11):e28626. PMID: 33480469.
      View in: PubMed
    34. Koo J, Giller RH, Quinones R, McKinney CM, Verneris MR, Knight-Perry J. Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects. Pediatr Blood Cancer. 2020 09; 67(9):e28591. PMID: 32658382.
      View in: PubMed
    35. Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 04 14; 4(7):1350-1356. PMID: 32267930.
      View in: PubMed
    36. Tufa DM, Shank T, Yingst AM, Trahan GD, Shim S, Lake J, Woods R, Jones K, Verneris MR. Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage. Sci Rep. 2020 04 14; 10(1):6335. PMID: 32286456.
      View in: PubMed
    37. Sarhan D, Wang J, Sunil Arvindam U, Hallstrom C, Verneris MR, Grzywacz B, Warlick E, Blazar BR, Miller JS. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. JCI Insight. 2020 03 12; 5(5). PMID: 32045384.
      View in: PubMed
    38. Sachs K, Sarver AL, Noble-Orcutt KE, LaRue RS, Antony ML, Chang D, Lee Y, Navis CM, Hillesheim AL, Nykaza IR, Ha NA, Hansen CJ, Karadag FK, Bergerson RJ, Verneris MR, Meredith MM, Schomaker ML, Linden MA, Myers CL, Largaespada DA, Sachs Z. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia. Cancer Res. 2020 02 01; 80(3):458-470. PMID: 31784425.
      View in: PubMed
    39. Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, Verneris MR, Borowitz MJ, Shah NN, Gossai N, Shaw PJ, Chen AR, Schultz KR, Kreyenberg H, Di Maio L, Cazzaniga G, Eckert C, van der Velden VHJ, Sutton R, Lankester A, Peters C, Klingebiel TE, Willasch AM, Grupp SA, Pulsipher MA. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019 11 12; 3(21):3393-3405. PMID: 31714961.
      View in: PubMed
    40. Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG. Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):606-611. PMID: 31715306.
      View in: PubMed
    41. Knight JM, Rizzo JD, Wang T, He N, Logan BR, Spellman SR, Lee SJ, Verneris MR, Arevalo JMG, Cole SW. Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz073. PMID: 31763620.
      View in: PubMed
    42. Tsamadou C, F?rst D, Wang T, He N, Lee SJ, Spellman SR, Fleischhauer K, Hsu KC, Paczesny S, Verneris MR, Schrezenmeier H, Mytilineos J. Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia. Biol Blood Marrow Transplant. 2019 12; 25(12):2357-2365. PMID: 31425756.
      View in: PubMed
    43. Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv. 2019 07 09; 3(13):1926-1929. PMID: 31243002.
      View in: PubMed
    44. Lou H, Li H, Ho KJ, Cai LL, Huang AS, Shank TR, Verneris MR, Nickerson ML, Dean M, Anderson SK. The Human TET2 Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities. Front Cell Dev Biol. 2019; 7:99. PMID: 31231651.
      View in: PubMed
    45. Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, Lundquist K, Nguyen T, Ogolla S, Black J, Galambos C, Gumbart JC, Dawany N, Kelsen JR, de Zoeten EF, Quinones R, Eissa H, Verneris MR, Sullivan KE, Rochford R, Blish CA, Kedl RM, Dutmer CM, Hsieh EWY. Correction: A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation. J Exp Med. 2019 Jun 03; 216(6):1465. PMID: 31088899.
      View in: PubMed
    46. Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, Lundquist K, Nguyen T, Ogolla S, Black J, Galambos C, Gumbart JC, Dawany N, Kelsen JR, de Zoeten EF, Quinones R, Eissa H, Verneris MR, Sullivan KE, Rochford R, Blish CA, Kedl RM, Dutmer CM, Hsieh EWY. A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation. J Exp Med. 2019 06 03; 216(6):1255-1267. PMID: 31040184.
      View in: PubMed
    47. Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, Stefanski H, Elfeky R, Giller R, Mitchell R, Milano F, O'Brien TA, Dahlberg A, Delaney C, Kurtzberg J, Verneris MR, Boelens JJ. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Adv. 2019 04 09; 3(7):1118-1128. PMID: 30952678.
      View in: PubMed
    48. Green JS, Shanley RM, Brunstein CG, Young JH, Verneris MR. Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection. Transpl Infect Dis. 2019 Jun; 21(3):e13070. PMID: 30864271.
      View in: PubMed
    49. Tufa DM, Yingst AM, Shank T, Shim S, Trahan GD, Lake J, Woods R, Jones KL, Verneris MR. Transient Expression of GATA3 in Hematopoietic Stem Cells Facilitates Helper Innate Lymphoid Cell Differentiation. Front Immunol. 2019; 10:510. PMID: 30949172.
      View in: PubMed
    50. Koo J, Silverman S, Nuechterlein B, Keating AK, Verneris MR, Foreman NK, Mulcahy Levy JM. Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors. Bone Marrow Transplant. 2019 10; 54(10):1605-1613. PMID: 30783209.
      View in: PubMed
    51. Sopfe J, Pyle L, Keating AK, Campbell K, Liu AK, Wadwa RP, Verneris MR, Giller RH, Forlenza GP. Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. Blood Adv. 2019 02 12; 3(3):350-359. PMID: 30718242.
      View in: PubMed
    52. Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR. Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2019 05; 25(5):883-890. PMID: 30625388.
      View in: PubMed
    53. Askar M, Sayer D, Wang T, Haagenson M, Spellman SR, Lee SJ, Madbouly A, Fleischhauer K, Hsu KC, Verneris MR, Thomas D, Zhang A, Sobecks RM, Majhail NS. Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2019 04; 25(4):664-672. PMID: 30537553.
      View in: PubMed
    54. Pingel J, Wang T, Hagenlocher Y, Hern?ndez-Frederick CJ, Nagler A, Haagenson MD, Fleischhauer K, Hsu KC, Verneris MR, Lee SJ, Mohty M, Polge E, Spellman SR, Schmidt AH, van Rood JJ. The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR. Bone Marrow Transplant. 2019 06; 54(6):849-857. PMID: 30279575.
      View in: PubMed
    55. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018 10; 24(10):1504-1506. PMID: 30275569.
      View in: PubMed
    56. Woolfrey A, Wang T, Lee SJ, Haagenson MD, Chen G, Fleischhauer K, Horan J, Hsu K, Verneris M, Spellman SR, Fernandez-Vina M. Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. Bone Marrow Transplant. 2019 03; 54(3):494-496. PMID: 30232414.
      View in: PubMed
    57. Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, Diaz MA, Badawy SM, Broglie L, Brown V, Dvorak CC, Gonzalez-Vicent M, Hashem H, Hayashi RJ, Jacobsohn DA, Kent MW, Li CK, Margossian SP, Martin PL, Mehta P, Myers K, Olsson R, Page K, Pulsipher MA, Shaw PJ, Smith AR, Triplett BM, Verneris MR, Eapen M. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2019 02; 25(2):301-306. PMID: 30244103.
      View in: PubMed
    58. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR. Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2019 01; 25(1):12-18. PMID: 30144561.
      View in: PubMed
    59. Arrieta-Bola?os E, Crivello P, Shaw BE, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. Blood Adv. 2018 07 24; 2(14):1773-1783. PMID: 30042143.
      View in: PubMed
    60. Rothenberger M, Wagner JE, Haase A, Richman D, Grzywacz B, Strain M, Lada S, Estes J, Fletcher CV, Podany AT, Anderson J, Schmidt T, Wietgrefe S, Schacker T, Verneris MR. Transplantation of CCR5?32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection. Open Forum Infect Dis. 2018 May; 5(5):ofy090. PMID: 29868623.
      View in: PubMed
    61. Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2018 08; 24(8):1651-1656. PMID: 29753157.
      View in: PubMed
    62. Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018 04 24; 2(8):909-922. PMID: 29678809.
      View in: PubMed
    63. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018 06 07; 131(23):2515-2527. PMID: 29463563.
      View in: PubMed
    64. Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, Horowitz MM, Verneris M, Hsu KC, Fleischhauer K, Lee SJ. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biol Blood Marrow Transplant. 2018 05; 24(5):1049-1056. PMID: 29454040.
      View in: PubMed
    65. Buturovic L, Shelton J, Spellman SR, Wang T, Friedman L, Loftus D, Hesterberg L, Woodring T, Fleischhauer K, Hsu KC, Verneris MR, Haagenson M, Lee SJ. Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection. Biol Blood Marrow Transplant. 2018 06; 24(6):1299-1306. PMID: 29410341.
      View in: PubMed
    66. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 02 01; 378(5):439-448. PMID: 29385370.
      View in: PubMed
    67. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):932-937. PMID: 29382954.
      View in: PubMed
    68. Lee C, Haneuse S, Wang HL, Rose S, Spellman SR, Verneris M, Hsu KC, Fleischhauer K, Lee SJ, Abdi R. Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. PLoS One. 2018; 13(1):e0190610. PMID: 29346409.
      View in: PubMed
    69. Gadalla SM, Wang T, Loftus D, Friedman L, Dagnall C, Haagenson M, Spellman SR, Buturovic L, Blauwkamp M, Shelton J, Fleischhauer K, Hsu KC, Verneris MR, Krstajic D, Hicks B, Jones K, Lee SJ, Savage SA. No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant. 2018 04; 53(4):383-391. PMID: 29269807.
      View in: PubMed
    70. Williams RL, Cooley S, Bachanova V, Blazar BR, Weisdorf DJ, Miller JS, Verneris MR. Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant. 2018 03; 24(3):618-622. PMID: 29197679.
      View in: PubMed
    71. William BM, Wang T, Haagenson MD, Fleischhauer K, Verneris M, Hsu KC, de Lima MJ, Fernandez-Vi?a M, Spellman SR, Lee SJ, Hill BT. Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018 04; 24(4):827-831. PMID: 29155319.
      View in: PubMed
    72. Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG. Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402. Bone Marrow Transplant. 2018 01; 53(1):64-68. PMID: 29058696.
      View in: PubMed
    73. Pilbeam K, Wang H, Taras E, Bergerson RJ, Ettestad B, DeFor T, Borgatti A, Vallera DA, Verneris MR. Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. Oncotarget. 2018 Feb 23; 9(15):11938-11947. PMID: 29552283.
      View in: PubMed
    74. Touma W, Brunstein CG, Cao Q, Miller JS, Curtsinger J, Verneris MR, Bachanova V. Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1925-1931. PMID: 28729150.
      View in: PubMed
    75. Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A. Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402. Bone Marrow Transplant. 2017 Sep; 52(9):1300-1303. PMID: 28581470.
      View in: PubMed
    76. Fleischhauer K, Ahn KW, Wang HL, Zito L, Crivello P, M?ller C, Verneris M, Shaw BE, Pidala J, Oudshorn M, Lee SJ, Spellman SR. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2017 Sep; 52(9):1280-1287. PMID: 28581467.
      View in: PubMed
    77. Angelos MG, Ruh PN, Webber BR, Blum RH, Ryan CD, Bendzick L, Shim S, Yingst AM, Tufa DM, Verneris MR, Kaufman DS. Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood. 2017 06 29; 129(26):3428-3439. PMID: 28533309.
      View in: PubMed
    78. Hui S, Brunstein C, Takahashi Y, DeFor T, Holtan SG, Bachanova V, Wilke C, Zuro D, Ustun C, Weisdorf D, Dusenbery K, Verneris MR. Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1110-1116. PMID: 28396164.
      View in: PubMed
    79. Dourado KMC, Baik J, Oliveira VKP, Beltrame M, Yamamoto A, Theuer CP, Figueiredo CAV, Verneris MR, Perlingeiro RCR. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. Blood. 2017 05 04; 129(18):2526-2536. PMID: 28351936.
      View in: PubMed
    80. Madbouly A, Wang T, Haagenson M, Paunic V, Vierra-Green C, Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR, Maiers M. Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes. Biol Blood Marrow Transplant. 2017 Jun; 23(6):1029-1037. PMID: 28263917.
      View in: PubMed
    81. Mitchell R, Wagner JE, Brunstein C, Cao Q, McKenna DH, Verneris MR. Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2017 May; 23(5):836-839. PMID: 28214595.
      View in: PubMed
    82. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547. PMID: 28177873.
      View in: PubMed
    83. Magome T, Froelich J, Holtan SG, Takahashi Y, Verneris MR, Brown K, Dusenbery K, Wong J, Hui SK. Whole-Body Distribution of Leukemia and Functional Total Marrow Irradiation Based on FLT-PET and Dual-Energy CT. Mol Imaging. 2017 Jan-Dec; 16:1536012117732203. PMID: 28948859.
      View in: PubMed
    84. Askar M, Sobecks R, Wang T, Haagenson M, Majhail N, Madbouly A, Thomas D, Zhang A, Fleischhauer K, Hsu K, Verneris M, Lee SJ, Spellman SR, Fern?ndez-Vi?a M. MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2017 Mar; 23(3):436-444. PMID: 27987385.
      View in: PubMed
    85. He F, Verneris MR, Cooley S, Blazar BR, MacMillan ML, Newell LF, Panoskaltsis-Mortari A, DeFor T, Weisdorf DJ, Holtan SG. Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2017 02; 52(2):301-303. PMID: 27869812.
      View in: PubMed
    86. Lu H, Bhoopatiraju S, Wang H, Schmitz NP, Wang X, Freeman MJ, Forster CL, Verneris MR, Linden MA, Hallstrom TC. Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. Oncotarget. 2016 Nov 15; 7(46):76047-76061. PMID: 27738314.
      View in: PubMed
    87. Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017 02 09; 129(6):740-758. PMID: 27821506.
      View in: PubMed
    88. Bergerson RJ, Williams R, Wang H, Shanley R, Colbenson G, Kerber A, Cooley S, Curtsinger J, Felices M, Miller JS, Verneris MR. Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 Response. Blood Adv. 2016 Dec 27; 1(3):208-218. PMID: 29188237.
      View in: PubMed
    89. Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK. Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Transplant. 2017 01; 23(1):126-133. PMID: 27989929.
      View in: PubMed
    90. Hoff GA, Fischer JC, Hsu K, Cooley S, Miller JS, Wang T, Haagenson M, Spellman S, Lee SJ, Uhrberg M, Venstrom JM, Verneris MR. Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2017 01; 23(1):153-160. PMID: 27746218.
      View in: PubMed
    91. Pritchett JC, Green JS, Thomm AM, Knox KK, Verneris MR, Lund TC. CD4+ T Cells Coexpressing CD134 (OX40) Harbor Significantly Increased Levels of Human Herpesvirus 6B DNA Following Umbilical Cord Blood Transplantation. J Infect Dis. 2016 Dec 15; 214(12):1911-1915. PMID: 27703035.
      View in: PubMed
    92. Goyal RK, Lee SJ, Wang T, Trucco M, Haagenson M, Spellman SR, Verneris M, Ferrell RE. Novel HLA-DP region susceptibility loci associated with severe acute GvHD. Bone Marrow Transplant. 2017 Jan; 52(1):95-100. PMID: 27595289.
      View in: PubMed
    93. Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):2025-2030. PMID: 27519278.
      View in: PubMed
    94. Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res. 2016 10 01; 76(19):5696-5706. PMID: 27503932.
      View in: PubMed
    95. Turcotte LM, Yingst A, Verneris MR. Erratum to: "Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction" [Biol Blood Marrow Transplant 2016;22:1159-1166]. Biol Blood Marrow Transplant. 2016 12; 22(12):2286. PMID: 27500528.
      View in: PubMed
    96. Kornblit B, Wang T, Lee SJ, Spellman SR, Zhu X, Fleischhauer K, M?ller C, Verneris MR, M?ller K, Johansen JS, Vindelov L, Garred P. YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome. Bone Marrow Transplant. 2016 Dec; 51(12):1556-1560. PMID: 27427920.
      View in: PubMed
    97. Magome T, Froelich J, Takahashi Y, Arentsen L, Holtan S, Verneris MR, Brown K, Haga A, Nakagawa K, Holter Chakrabarty JL, Giebel S, Wong J, Dusenbery K, Storme G, Hui SK. Evaluation of Functional Marrow Irradiation Based on Skeletal Marrow Composition Obtained Using Dual-Energy Computed Tomography. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):679-87. PMID: 27681765.
      View in: PubMed
    98. Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JH, Auletta J, Komanduri KV, Lindemans C, Riches ML. Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 09; 22(9):1636-1645. PMID: 27343716.
      View in: PubMed
    99. Phelan R, Mann E, Napurski C, DeFor TE, Petryk A, Miller WP, Wagner JE, Verneris MR, Smith AR. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. Bone Marrow Transplant. 2016 Oct; 51(10):1369-1375. PMID: 27272448.
      View in: PubMed
    100. Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, M?ller CR, Fernandez-Vi?a MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016 10; 101(10):1267-1274. PMID: 27247320.
      View in: PubMed
    101. Arora M, Lee SJ, Spellman SR, Weisdorf DJ, Guan W, Haagenson M, Wang T, Horowitz MH, Verneris MR, Fleischhauer K, Hsu K, Thyagarajan B. Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1531-1532. PMID: 27155583.
      View in: PubMed
    102. Eckfeldt CE, Randall N, Shanley RM, Yohe S, Bejanyan N, Dolan M, Warlick ED, Verneris MR, Brunstein CG, Wagner JE, Weisdorf DJ, Ustun C. Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. Haematologica. 2016 08; 101(8):e348-51. PMID: 27125981.
      View in: PubMed
    103. He F, Warlick E, Miller JS, MacMillan M, Verneris MR, Cao Q, Weisdorf D. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant. 2016 Aug; 51(8):1107-12. PMID: 27064686.
      View in: PubMed
    104. Turcotte LM, Yingst A, Verneris MR. Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction. Biol Blood Marrow Transplant. 2016 07; 22(7):1159-1166. PMID: 27013015.
      View in: PubMed
    105. Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016 07 15; 22(14):3440-50. PMID: 26847056.
      View in: PubMed
    106. Knorr DA, Wang H, Aurora M, MacMillan ML, Holtan SG, Bergerson R, Cao Q, Weisdorf DJ, Cooley S, Brunstein C, Miller JS, Wagner JE, Blazar BR, Verneris MR. Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 May; 22(5):825-33. PMID: 26806586.
      View in: PubMed
    107. Cichocki F, Verneris MR, Cooley S, Bachanova V, Brunstein CG, Blazar BR, Wagner J, Schlums H, Bryceson YT, Weisdorf DJ, Miller JS. The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Curr Top Microbiol Immunol. 2016; 395:225-43. PMID: 26037048.
      View in: PubMed
    108. Wilke C, Holtan SG, Sharkey L, DeFor T, Arora M, Premakanthan P, Yohe S, Vagge S, Zhou D, Holter Chakrabarty JL, Mahe M, Corvo R, Dusenbery K, Storme G, Weisdorf DJ, Verneris MR, Hui S. Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen. Radiother Oncol. 2016 Jan; 118(1):65-71. PMID: 26653357.
      View in: PubMed
    109. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016 Feb 25; 127(8):1044-51. PMID: 26563133.
      View in: PubMed
    110. Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J. 2015 Nov-Dec; 21(6):486-91. PMID: 26588681.
      View in: PubMed
    111. Turcotte LM, Verneris MR. Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant. Clin Cancer Res. 2016 Jan 01; 22(1):6-8. PMID: 26482045.
      View in: PubMed
    112. Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, Brunstein C, Wagner JE, Verneris MR, Weisdorf D. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015 Oct; 90(10):892-6. PMID: 26149534.
      View in: PubMed
    113. Brunstein CG, Petersdorf EW, DeFor TE, Noreen H, Maurer D, MacMillan ML, Ustun C, Verneris MR, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):487-92. PMID: 26431630.
      View in: PubMed
    114. Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, Brunstein CG, Blazar BR, Wagner J, Diamond DJ, Verneris MR, Bryceson YT, Weisdorf DJ, Miller JS. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016 Feb; 30(2):456-63. PMID: 26416461.
      View in: PubMed
    115. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2154-2159. PMID: 26327632.
      View in: PubMed
    116. Ahn YO, Weeres MA, Neulen ML, Choi J, Kang SH, Heo DS, Bergerson R, Blazar BR, Miller JS, Verneris MR. Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. Eur J Immunol. 2015 Aug; 45(8):2335-42. PMID: 26046454.
      View in: PubMed
    117. Verneris MR, Lee SJ, Ahn KW, Wang HL, Battiwalla M, Inamoto Y, Fernandez-Vina MA, Gajewski J, Pidala J, Munker R, Aljurf M, Saber W, Spellman S, Koreth J. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1783-9. PMID: 26055300.
      View in: PubMed
    118. Davis ZB, Cooley SA, Cichocki F, Felices M, Wangen R, Luo X, DeFor TE, Bryceson YT, Diamond DJ, Brunstein C, Blazar BR, Wagner JE, Weisdorf DJ, Horowitz A, Guethlein LA, Parham P, Verneris MR, Miller JS. Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1653-62. PMID: 26055301.
      View in: PubMed
    119. Sobecks RM, Wang T, Askar M, Gallagher MM, Haagenson M, Spellman S, Fernandez-Vina M, Malmberg KJ, M?ller C, Battiwalla M, Gajewski J, Verneris MR, Ringd?n O, Marino S, Davies S, Dehn J, Bornh?user M, Inamoto Y, Woolfrey A, Shaw P, Pollack M, Weisdorf D, Milller J, Hurley C, Lee SJ, Hsu K. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1589-96. PMID: 25960307.
      View in: PubMed
    120. Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar 15; 21(6):1267-72. PMID: 25770294.
      View in: PubMed
    121. Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1029-36. PMID: 25759146.
      View in: PubMed
    122. Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014 Oct 30; 371(18):1685-94. PMID: 25354103.
      View in: PubMed
    123. Takahashi Y, Vagge S, Agostinelli S, Han E, Matulewicz L, Schubert K, Chityala R, Ratanatharathorn V, Tournel K, Penagaricano JA, Florian S, Mahe MA, Verneris MR, Weisdorf DJ, Corvo R, Dusenbery KE, Storme G, Hui SK. Multi-institutional feasibility study of a fast patient localization method in total marrow irradiation with helical tomotherapy: a global health initiative by the international consortium of total marrow irradiation. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):30-8. PMID: 25442340.
      View in: PubMed
    124. Verneris MR, Miller JS. KIR B or not to be?...that is the question for ALL. Blood. 2014 Oct 23; 124(17):2623-4. PMID: 25342666.
      View in: PubMed
    125. Ross JA, Tolar J, Spector LG, DeFor T, Lund TC, Weisdorf DJ, Langer E, Hooten AJ, Thyagarajan B, Gleason MK, Wagner JE, Robien K, Verneris MR. An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):81-8. PMID: 25300867.
      View in: PubMed
    126. Mitchell R, Wagner JE, Brunstein CG, Cao Q, McKenna DH, Lund TC, Verneris MR. Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):50-4. PMID: 25262882.
      View in: PubMed
    127. Felices M, Ankarlo DE, Lenvik TR, Nelson HH, Blazar BR, Verneris MR, Miller JS. Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation. J Immunol. 2014 Oct 01; 193(7):3344-54. PMID: 25172483.
      View in: PubMed
    128. Weeres MA, Robien K, Ahn YO, Neulen ML, Bergerson R, Miller JS, Verneris MR. The effects of 1,25-dihydroxyvitamin D3 on in vitro human NK cell development from hematopoietic stem cells. J Immunol. 2014 Oct 01; 193(7):3456-62. PMID: 25149465.
      View in: PubMed
    129. Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014 Sep; 89(9):889-95. PMID: 24891274.
      View in: PubMed
    130. Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant. 2014 Aug; 49(8):1029-35. PMID: 24887379.
      View in: PubMed
    131. Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7. PMID: 24816582.
      View in: PubMed
    132. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014 Jun 19; 123(25):3855-63. PMID: 24719405.
      View in: PubMed
    133. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014 May 08; 123(19):3016-26. PMID: 24652987.
      View in: PubMed
    134. Sengsayadeth S, Wang T, Lee SJ, Haagenson MD, Spellman S, Fernandez Vi?a MA, Muller CR, Verneris MR, Savani BN, Jagasia M. Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2014 Jun; 20(6):900-3. PMID: 24631737.
      View in: PubMed
    135. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014 Apr; 26(2):161-72. PMID: 24618042.
      View in: PubMed
    136. Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014 Mar; 258(1):45-63. PMID: 24517425.
      View in: PubMed
    137. Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). Bone Marrow Transplant. 2014 Mar; 49(3):440-2. PMID: 24317126.
      View in: PubMed
    138. Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR. Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014 Feb; 49(2):174-8. PMID: 24185590.
      View in: PubMed
    139. Sawitzki B, Brunstein C, Meisel C, Schumann J, Vogt K, Appelt C, Curtsinger JM, Verneris MR, Miller JS, Wagner JE, Blazar BR. Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant. 2014 Feb; 20(2):173-82. PMID: 24184334.
      View in: PubMed
    140. Takahashi Y, Verneris MR, Dusenbery KE, Wilke CT, Storme G, Weisdorf DJ, Hui SK. Peripheral dose heterogeneity due to the thread effect in total marrow irradiation with helical tomotherapy. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):832-9. PMID: 24011657.
      View in: PubMed
    141. Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C. How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. Am J Hematol. 2013 Sep; 88(9):826-7. PMID: 23737091.
      View in: PubMed
    142. Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013 Jul 15; 19(14):3844-55. PMID: 23690482.
      View in: PubMed
    143. Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013 May; 28(4):274-82. PMID: 23611188.
      View in: PubMed
    144. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1021-5. PMID: 23567175.
      View in: PubMed
    145. Aldoss O, Gruenstein DH, Bass JL, Steinberger J, Zhang Y, Defor TE, Tolar J, Verneris MR, Orchard PJ. Pericardial effusion after pediatric hematopoietic cell transplant. Pediatr Transplant. 2013 May; 17(3):294-9. PMID: 23464863.
      View in: PubMed
    146. Ahn YO, Blazar BR, Miller JS, Verneris MR. Lineage relationships of human interleukin-22-producing CD56+ ROR?t+ innate lymphoid cells and conventional natural killer cells. Blood. 2013 Mar 21; 121(12):2234-43. PMID: 23327921.
      View in: PubMed
    147. Verneris MR. Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. Hematology Am Soc Hematol Educ Program. 2013; 2013:335-41. PMID: 24319201.
      View in: PubMed
    148. Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR. Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. Pediatr Blood Cancer. 2013 Apr; 60(4):705-10. PMID: 23152304.
      View in: PubMed
    149. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012 Nov 15; 189(10):5082-8. PMID: 23077239.
      View in: PubMed
    150. Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012 Dec; 11(12):2674-84. PMID: 23075808.
      View in: PubMed
    151. Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR. Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1):138-42. PMID: 22960388.
      View in: PubMed
    152. Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA, Stefanski H, Brunstein C, Cooley S, Miller JS, Blazar BR, Wagner JE, Verneris MR. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1):109-16. PMID: 22940056.
      View in: PubMed
    153. Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant. 2012 Jun; 18(6):963-8. PMID: 22430088.
      View in: PubMed
    154. Verneris M, Wagner JE. The epic race to immune reconstitution. Biol Blood Marrow Transplant. 2012 Apr; 18(4):493-4. PMID: 22338627.
      View in: PubMed
    155. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, Niki T, Hirashima M, Blazar BR, Miller JS. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012 Mar 29; 119(13):3064-72. PMID: 22323453.
      View in: PubMed
    156. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Verg?s S, Lanier LL, Weisdorf D, Miller JS. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012 Mar 15; 119(11):2665-74. PMID: 22180440.
      View in: PubMed
    157. Wenner CA, Martzen MR, Lu H, Verneris MR, Wang H, Slaton JW. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. Int J Oncol. 2012 Apr; 40(4):905-13. PMID: 22159900.
      View in: PubMed
    158. Warlick ED, DeFor T, Blazar BR, Burns L, Verneris MR, Ustun C, Weisdorf DJ, Miller JS. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Mar; 18(3):480-6. PMID: 22155141.
      View in: PubMed
    159. Dezell SA, Ahn YO, Spanholtz J, Wang H, Weeres M, Jackson S, Cooley S, Dolstra H, Miller JS, Verneris MR. Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods. Biol Blood Marrow Transplant. 2012 Apr; 18(4):536-45. PMID: 22155502.
      View in: PubMed
    160. Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012 Jun; 18(6):930-6. PMID: 22108570.
      View in: PubMed
    161. Rizwan R, Levine JE, Defor T, Ferarra JL, Weisdorf DJ, Blazar BR, Verneris MR. Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation. Am J Hematol. 2011 Oct; 86(10):879-82. PMID: 21922528.
      View in: PubMed
    162. Ramirez P, Wagner JE, DeFor TE, Blazar BR, Verneris MR, Miller JS, McKenna DH, Weisdorf DJ, McGlave PB, Brunstein CG. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant. 2012 Jun; 47(6):799-803. PMID: 21946383.
      View in: PubMed
    163. Burke MJ, Lindgen B, Verneris MR. Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. Pediatr Blood Cancer. 2012 Jun; 58(6):840-5. PMID: 21796765.
      View in: PubMed
    164. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Weisdorf DJ, Miller JS. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood. 2011 Sep 08; 118(10):2784-92. PMID: 21757615.
      View in: PubMed
    165. Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011 May 12; 117(19):5261-3. PMID: 21403127.
      View in: PubMed
    166. Tang Q, Ahn YO, Southern P, Blazar BR, Miller JS, Verneris MR. Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue. Blood. 2011 Apr 14; 117(15):4052-5. PMID: 21310921.
      View in: PubMed
    167. Grzywacz B, Kataria N, Kataria N, Blazar BR, Miller JS, Verneris MR. Natural killer-cell differentiation by myeloid progenitors. Blood. 2011 Mar 31; 117(13):3548-58. PMID: 21173117.
      View in: PubMed
    168. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1025-32. PMID: 21047561.
      View in: PubMed
    169. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant. 2011 Jul; 46(7):950-5. PMID: 20856210.
      View in: PubMed
    170. Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant. 2011 Jun; 17(6):831-40. PMID: 20831896.
      View in: PubMed
    171. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, Verneris MR, Appelbaum FR, Wagner JE, Delaney C. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010 Nov 25; 116(22):4693-9. PMID: 20686119.
      View in: PubMed
    172. Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep. 2010 Jul; 5(3):157-62. PMID: 20446122.
      View in: PubMed
    173. Ahn YO, Weigel B, Verneris MR. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res. 2010 Aug 01; 16(15):3819-21. PMID: 20554750.
      View in: PubMed
    174. Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR. Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone Marrow Transplant. 2011 Mar; 46(3):368-71. PMID: 20548337.
      View in: PubMed
    175. Beck JC, Verneris MR. The TREC to less CMV after UCBT. Blood. 2010 May 20; 115(20):4009-10. PMID: 20489061.
      View in: PubMed
    176. Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1237-44. PMID: 20302960.
      View in: PubMed
    177. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010 May; 16(5):612-21. PMID: 20139023.
      View in: PubMed
    178. Verneris MR, Wagner JE. UCB and atmospheric noise. Blood. 2010 Jan 28; 115(4):754-5. PMID: 20110431.
      View in: PubMed
    179. Verneris MR, Grupp SA. Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time? J Clin Oncol. 2010 Feb 20; 28(6):909-10. PMID: 20085932.
      View in: PubMed
    180. Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol. 2010; 651:61-77. PMID: 20686960.
      View in: PubMed
    181. Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer. 2010 Jan; 54(1):138-43. PMID: 19693941.
      View in: PubMed
    182. Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2009 Dec 15; 53(7):1289-94. PMID: 19731318.
      View in: PubMed
    183. Anderson E, Grzywacz B, Wang H, Wang T, Haagenson M, Spellman S, Blazar BR, Miller JS, Verneris MR. Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation. Blood. 2009 Nov 19; 114(21):4753-4; author reply 4754-5. PMID: 19965715.
      View in: PubMed
    184. Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol. 2009 Oct; 147(2):185-91. PMID: 19796267.
      View in: PubMed
    185. Beck JC, Wagner JE, DeFor TE, Brunstein CG, Schleiss MR, Young JA, Weisdorf DH, Cooley S, Miller JS, Verneris MR. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010 Feb; 16(2):215-22. PMID: 19786112.
      View in: PubMed
    186. Smith AR, Baker KS, Defor TE, Verneris MR, Wagner JE, Macmillan ML. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1086-93. PMID: 19660721.
      View in: PubMed
    187. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 05; 114(19):4293-9. PMID: 19706886.
      View in: PubMed
    188. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Aug 01; 27(22):3634-41. PMID: 19581540.
      View in: PubMed
    189. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009 Jun 11; 113(24):6094-101. PMID: 19365083.
      View in: PubMed
    190. Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, DeFor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009 May 28; 113(22):5628-34. PMID: 19329778.
      View in: PubMed
    191. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Aug; 44(3):169-74. PMID: 19204709.
      View in: PubMed
    192. Hui SK, Verneris MR, Froelich J, Dusenbery K, Welsh JS. Multimodality image guided total marrow irradiation and verification of the dose delivered to the lung, PTV, and thoracic bone in a patient: a case study. Technol Cancer Res Treat. 2009 Feb; 8(1):23-8. PMID: 19166239.
      View in: PubMed
    193. Harvey SB, Zhang Y, Wilson-Grady J, Monkkonen T, Nelsestuen GL, Kasthuri RS, Verneris MR, Lund TC, Ely EW, Bernard GR, Zeisler H, Homoncik M, Jilma B, Swan T, Kellogg TA. O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J Proteome Res. 2009 Feb; 8(2):603-12. PMID: 19055479.
      View in: PubMed
    194. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Mar 26; 113(13):2902-5. PMID: 19179301.
      View in: PubMed
    195. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, Blazar BR, Wagner JE. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009 Mar 12; 113(11):2410-5. PMID: 18997171.
      View in: PubMed
    196. Tang Q, Grzywacz B, Wang H, Kataria N, Cao Q, Wagner JE, Blazar BR, Miller JS, Verneris MR. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol. 2008 Oct 01; 181(7):4507-15. PMID: 18802053.
      View in: PubMed
    197. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009 Jan; 43(2):107-13. PMID: 18776928.
      View in: PubMed
    198. Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):467-83. PMID: 18790450.
      View in: PubMed
    199. Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Biol Blood Marrow Transplant. 2008 Jun; 14(6):685-92. PMID: 18489994.
      View in: PubMed
    200. Grupp SA, Verneris M, Sondel PM, Cooper LJ. Immunotherapy for pediatric cancer. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):33-43. PMID: 18162219.
      View in: PubMed
    201. Jacobson PA, Rydhom N, Huang J, Baker KS, Verneris MR. High-unbound mycophenolic acid concentrations in an infant on peritoneal dialysis following hematopoietic cell transplant. Bone Marrow Transplant. 2007 Nov; 40(9):911-2. PMID: 17724439.
      View in: PubMed
    202. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, Cooley S, Wangen R, Fautsch SK, Nicklow R, Defor T, Blazar BR. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007 Oct 01; 110(7):2761-3. PMID: 17579184.
      View in: PubMed
    203. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, Blazar BR, Cornfield DN, Miller JS, Verneris MR. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007 Sep 01; 110(5):1530-9. PMID: 17495133.
      View in: PubMed
    204. Verneris MR, Wagner JE. Recent developments in cell-based immune therapy for neuroblastoma. J Neuroimmune Pharmacol. 2007 Jun; 2(2):134-9. PMID: 18040838.
      View in: PubMed
    205. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007 Jun 01; 109(11):5058-61. PMID: 17317850.
      View in: PubMed
    206. Lund TC, Anderson LB, McCullar V, Higgins L, Yun GH, Grzywacz B, Verneris MR, Miller JS. iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types. J Proteome Res. 2007 Feb; 6(2):644-53. PMID: 17269721.
      View in: PubMed
    207. Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007 Feb; 21(2):356-9; author reply 359. PMID: 17251901.
      View in: PubMed
    208. Hui SK, Verneris MR, Higgins P, Gerbi B, Weigel B, Baker SK, Fraser C, Tomblyn M, Dusenbery K. Helical tomotherapy targeting total bone marrow - first clinical experience at the University of Minnesota. Acta Oncol. 2007; 46(2):250-5. PMID: 17453378.
      View in: PubMed
    209. Peters AM, Blair CK, Verneris MR, Neglia JP, Robison LL, Spector LG, Reaman GH, Felix CA, Ross JA. Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study. Br J Cancer. 2006 Nov 06; 95(9):1274-6. PMID: 17003777.
      View in: PubMed
    210. Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006 Dec 01; 108(12):3824-33. PMID: 16902150.
      View in: PubMed
    211. Kasthuri RS, Verneris MR, Ibrahim HN, Jilma B, Nelsestuen GL. Studying multiple protein profiles over time to assess biomarker validity. Expert Rev Proteomics. 2006 Aug; 3(4):455-64. PMID: 16901203.
      View in: PubMed
    212. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant. 2006 Jan; 37(2):175-81. PMID: 16273111.
      View in: PubMed
    213. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005 Dec 15; 175(12):7819-28. PMID: 16339517.
      View in: PubMed
    214. Nelsestuen GL, Zhang Y, Martinez MB, Key NS, Jilma B, Verneris M, Sinaiko A, Kasthuri RS. Plasma protein profiling: unique and stable features of individuals. Proteomics. 2005 Oct; 5(15):4012-24. PMID: 16130168.
      View in: PubMed
    215. Tan PL, Verneris MR, Charnas LR, Reck SJ, van Burik JA, Blazar BR. Outcome of CNS and pulmonary enteroviral infections after hematopoietic cell transplantation. Pediatr Blood Cancer. 2005 Jul; 45(1):74-5. PMID: 15806546.
      View in: PubMed
    216. Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karimi M, Karami M, Cao YA, Marina N, Contag CH, Negrin RS. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res. 2005 Jun 15; 11(12):4561-70. PMID: 15958642.
      View in: PubMed
    217. Peters A, Manivel JC, Dolan M, Gulbahce HE, Baker KS, Verneris MR. Pulmonary cytolytic thrombi after allogeneic hematopoietic cell transplantation: a further histologic description. Biol Blood Marrow Transplant. 2005 Jun; 11(6):484-5. PMID: 15931637.
      View in: PubMed
    218. Verneris MR, Karimi M, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004 Apr 15; 103(8):3065-72. PMID: 15070686.
      View in: PubMed
    219. Schrier SL, Centis F, Verneris M, Ma L, Angelucci E. The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep. 2003; 8(5):241-5. PMID: 14962357.
      View in: PubMed
    220. Verneris MR, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol. 2002 May; 22(3):131-6. PMID: 12078854.
      View in: PubMed
    221. Negrin RS, Edinger M, Verneris M, Cao YA, Bachmann M, Contag ChH. Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. Ann Hematol. 2002; 81 Suppl 2:S44-5. PMID: 12611073.
      View in: PubMed
    222. Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, Kornacker B, Staratschek-Jox A, Diehl V, Wolf J. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer. 2001 Nov; 94(4):513-9. PMID: 11745437.
      View in: PubMed
    223. Verneris M, McDougall IR, Becton D, Link MP. Thyroid carcinoma after successful treatment of osteosarcoma: a report of three patients. J Pediatr Hematol Oncol. 2001 Jun-Jul; 23(5):312-5. PMID: 11464990.
      View in: PubMed
    224. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001 May 15; 97(10):2923-31. PMID: 11342413.
      View in: PubMed
    225. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001 Apr 02; 76(3):169-73. PMID: 11306144.
      View in: PubMed
    226. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001; 7(10):532-42. PMID: 11760085.
      View in: PubMed
    227. Verneris MR, Kornacker M, Mail?nder V, Negrin RS. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 2000 Aug; 49(6):335-45. PMID: 10946816.
      View in: PubMed
    228. Verneris MR, Tuel L, Seibel NL. Pediatric HIV infection and chronic myelogenous leukemia. Pediatr AIDS HIV Infect. 1995 Oct; 6(5):292-4. PMID: 11361394.
      View in: PubMed
    Verneris's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (666) concept(s)
    _
    Co-Authors Expand Description
    See all (33) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)